Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan

Vaccine

Volumn 34, Issue 16, 2016, Pages 1975-1985

  Shimizu, Hiroyuki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Global polio eradication; Inactivated poliovirus vaccine; Oral poliovirus vaccine; Poliovirus; Poliovirus vaccine; Sabin strain; Vaccine associated paralytic poliomyelitis; Vaccine derived poliovirus

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

EPIDEMIC; HUMAN; IMMUNIZATION; JAPAN; MUCOSAL IMMUNITY; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VIRUS STRAIN; VIRUS TRANSMISSION; DISEASE OUTBREAKS; HISTORY; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; VACCINATION;

DISEASE OUTBREAKS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION PROGRAMS; JAPAN; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION;

EID: 84961057968     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.015     Document Type: Review

References (108)

1. World Health Organization Polio vaccines: WHO position paper, January 2014-recommendations. Vaccine 2014, 32:4117-4118.
2. World Health Organization Polio Eradication and Endgame Strategic Plan 2013-2018 2013, World Health Organization, 〈http://www.polioeradication.org/resourcelibrary/strategyandwork.aspx〉.
3. Global Polio Eradication Initiative Call for expressions of interest (EoI)-developing Sabin-inactivated polio vaccine (sIPV) 2012, Global Polio Eradication Initiative, 〈http://www.polioeradication.org/Portals/0/Document/Research/EOI_POL_20120427.pdf〉.
4. World Health Organization WHO global action plan to minimize poliovirus facility-associated risk after eradication of wild polioviruses and cessation of routine OPV use 2009, World Health Organization, 〈http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAP3_2009.pdf〉.
5. Dowdle W.R., Wolff C. Post-eradication poliovirus facility-associated community risks. Biologicals 2006, 34:127-132.
6. Hirai I. On the Hein Mwdin's disease. Jikazasshi 1910, 125:759-769. [in Japanese].
7. Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010, 172:1213-1229.
8. Kono R. Poliomyelitis in Japan. Annu Rep Inst Virus Res, Kyoto Univ 1960, 3:1-41.
9. Paul J.R. Poliomyelitis in Japan. Am J Hyg 1947, 45:206-218.
10. Takatsu T., Tagaya I., Hirayama M. Poliomyelitis in Japan during the period 1962-68 after the introduction of mass vaccination with Sabin vaccine. Bull World Health Organ 1973, 49:129-137.
11. Vaccine Administration Subcommittee Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. Jpn J Med Sci Biol 1966, 19:277-291.
12. Sutter R.W., Kew O.M., Cochi S.L., Aylward R.B. Poliovirus vaccine-live. Vaccines 2013, 598-645. Elsevier Saunders, Philadelphia, PA. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
13. Tagaya I., Nakao C., Hara M., Yamadera S. Characterization of poliovirus isolates in Japan after the mass vaccination with live oral poliomyelitis vaccine (Sabin). Bull World Health Organ 1973, 48:547-554.
14. Nakano J.H., Hatch M.H., Thieme M.L., Nottay B. Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog Med Virol 1978, 24:178-206. (Fortschritte der medizinischen Virusforschung Progres en virologie medicale).
15. Kitahara T., Hara M., Nakao C., Yamazaki Z., Soda K., Sasaki M., et al. Studies on the antigenic serodifferentiation of poliovirus strains. Jpn J Med Sci Biol 1963, 16:135-145.
16. Hara M., Arita M., Yamazaki Z., Hagiwara A., Saito Y. Antigenic and biochemical characterization of poliovirus type 1 isolates. Microbiol Immunol 1987, 31:327-336.
17. Hara M., Hagiwara A., Yoneyama T., Saito Y., Shimojo H. Antigenic and biochemical characterization of poliovirus type 1 isolates of non-vaccine origin. Microbiol Immunol 1983, 27:1057-1065.
18. Yoneyama T., Hagiwara A., Hara M. Structural proteins of poliovirus type 2 isolates. Microbiol Immunol 1981, 25:575-583.
19. Yoneyama T., Fujiwara T., Yokota Y., Takemika Y., Hagiwara A. Characterization of a wild poliovirus type 3 isolated Japan in 1993. Jpn J Med Sci Biol 1995, 48:61-70.
20. Abo W., Chiba S., Yamanaka T., Nakao T., Hara M., Tagaya I. Paralytic poliomyelitis in a child with agammaglobulinemia. Eur J Pediatr 1979, 132:11-16.
21. Yoneyama T., Hagiwara A., Hara M., Shimojo H. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect Immun 1982, 37:46-53.
22. Hara M., Saito Y., Komatsu T., Kodama H., Abo W., Chiba S., et al. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol 1981, 25:905-913.
23. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
24. National Committee for the Certification of Poliomyelitis Eradication of Japan Country progress report on maintaining polio-free status for the 18th regional commission for the certification of poliomyelitis eradication in the Western Pacific 2012, 1-12. National Committee for the Certification of Poliomyelitis Eradication of Japan, Tokyo, Japan.
25. Iwai M., Matsuura K., Hasegawa S., Obara M., Horimoto E., Nagai Y., et al. Isolation of vaccine-derived strain in epodemiological surveillnace of poliovirus. Annual report of Toyama Institute of Health 2005, 28:80-84. The publisher is Toyama Institute of Health (Imizu, Japan).
26. Adams A., Boualam L., Diorditsa S., Gregory C., Jee Y., Mendoza-Aldana J., et al. Maintaining polio-free certification in the World Health Organization Western Pacific Region for over a decade. J Infect Dis 2014, (in press).
27. Hennessey K., Schluter W.W., Wang X., Boualam L., Jee Y., Mendoza-Aldana J., et al. Are we there yet? Assessing achievement of vaccine-preventable disease goals in WHO's Western Pacific Region. Vaccine 2014, 32:4259-4266.
28. Maurice J. A second WHO region declared polio-free. Bull World Health Organ 2000, 78:1479.
29. Ozawa H., Noma S., Yoshida Y., Sekine H., Hashimoto T. Acute disseminated encephalomyelitis associated with poliomyelitis vaccine. Pediatr Neurol 2000, 23:177-179.
30. Inaba H., Hori H., Ito M., Kuze M., Ishiko H., Asmar B.I., et al. Polio vaccine virus-associated meningoencephalitis in an infant with transient hypogammaglobulinemia. Scand J Infect Dis 2001, 33:630-631.
31. Nakano T. Japanese vaccinations and practices, with particular attention to polio and pertussis. Travel Med Infect Dis 2011, 9:169-175.
32. Miyoshi M., Yoshizumi S., Jinushi M., Ishida S., Okui T., Okano M., et al. A case of paralytic poliomyelitis associated with poliovirus vaccine strains in hokkaido, Japan. Jpn J Infect Dis 2010, 63:216-217.
33. Higashigawa M., Maegawa K., Honma H., Yoshino A., Onozato K., Nashida Y., et al. Vaccine-associated paralytic poliomyelitis in an infant with perianal abscesses. J Infect Chemother. 2010, 16:356-359.
34. Asahina N., Matsunami Y., Sueda K., Shiraishi H., Saitoh S. Vaccine-associated paralytic poliomyelitis in a non-immunocompromised infant. Pediatr Int 2010, 52:838-841.
35. Hao L., Toyokawa S., Kobayashi Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis 2008, 61:100-103.
36. Ministry of Health Labour and Welfare. A conference material-The fist conference on smooth promotion for IPV introduction 2011, 16. 〈http://www.mhlw.go.jp/stf/shingi/2r9852000001nkzz-att/2r9852000001nl5a.pdf〉 [in Japanese].
37. Yamazaki S., Abe S. Developmemnt of Sabin strain-derived inactivated poliovirus vaccine in Japan. BIO Clinica 2011, 26:45-51. [in Japanese].
38. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M., et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006, 34:151-154.
39. Doi Y., Abe S., Yamamoto H., Horie H., Ohyama H., Satoh K., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. DevBiol 2001, 105:163-169.
40. Abe S., Tano Y., Ohta Y., Horie H., Miyazawa M., Wakabayashi K., et al. Development and clinical evaluation on the enhanced-potency inactivated poliovirus vaccine made from the Sabin strains. Clin Virol 1999, 27:248-261. [in Japanese].
41. Abe S., Yamaki A., Doi Y. Preparation of inactivated poliomyelitis vaccine with attenuated Sabin strains. Uirusu 1986, 36:125-137. [in Japanese].
42. World Health Organization WHO global action plan for laboratory containment of wild polioviruses 2004, World Health Organization, 〈http://www.biosafety.be/Polio/www729.pdf〉. 2nd ed.
43. Horie H., Miyazawa M., Ota Y., Wakabayashi K., Yoshida H., Doi Y., et al. Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells. Vaccine 2001, 19:1456-1459.
44. Ministry of Health Labour and Welfare. A conference material-the fist conference on smooth promotion for IPV introduction 2011, 7. 〈http://www.mhlw.go.jp/stf/shingi/2r9852000001nkzz-att/2r9852000001nl5a.pdf〉 [in Japanese].
45. Tano Y., Shimizu H., Martin J., Nishimura Y., Simizu B., Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25:7041-7046.
46. Martin J., Crossland G., Wood D.J., Minor P.D. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003, 84:1781-1788.
47. Kersten G., Hazendonk T., Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999, 17:2059-2066.
48. Sawyer L.A., Wood D., Ferguson M., Crainic R., Beuvery E.C., McInnis J., et al. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site. Biologicals 1997, 25:299-306.
49. Sawyer L.A., McInnis J., Albrecht P. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains. Biologicals 1993, 21:169-177.
50. Ferguson M., Wood D.J., Minor P.D. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 1993, 74(Pt 4):685-690.
51. Westdijk J., Koedam P., Barro M., Steil B.P., Collin N., Vedvick T.S., et al. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 2013, 31:1298-1304.
52. Thomassen Y.E., van'tOever A.G., van Oijen M.G., Wijffels R.H., van der Pol L.A., Bakker W.A. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One 2013, 8:e83374.
53. Westdijk J., Brugmans D., Martin J., van't Oever A., Bakker W.A., Levels L., et al. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011, 29:3390-3397.
54. Dragunsky E.M., Ivanov A.P., Abe S., Potapova S.G., Enterline J.C., Hashizume S., et al. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine. J Infect Dis 2006, 194:804-807.
55. Dragunsky E.M., Ivanov A.P., Wells V.R., Ivshina A.V., Rezapkin G.V., Abe S., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004, 190:1404-1412.
56. Shirato H., Someya Y., Ochiai M., Horiuchi Y., Takahashi M., Takeda N., et al. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014, 32:5163-5169.
57. Sato Y., Shiosaki K., Goto Y., Sonoda K., Kino Y. Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine. Biologicals 2013, 41:184-189.
58. Okada K., Miyazaki C., Kino Y., Ozaki T., Hirose M., Ueda K. Phase II and III clinical studies of Diphtheria-Tetanus-Acellular Pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis 2013, 208:275-283.
59. Ogawa H. Efficacy and safety of absorbed acellular pertussis-diphtheria-tetanus-Sabin strains derivd inactivated poliovirus combination vaccine. BIO Clin 2013, 28:72-79. [in Japanese].
60. Pharmaceuticals and Medical Devices Agency Review report-quattrovac subcutaneous injection syringe 2012, Pharmaceuticals and Medical Devices Agency, 〈http://www.pmda.go.jp/english/service/pdf/drugs/quattrovac_july2012_e.pdf〉.
61. Pharmaceuticals and Medical Devices Agency Review report-tetrabik subcutaneous injection syringe 2012, Pharmaceuticals and Medical Devices Agency, http://www.pmda.go.jp/english/service/pdf/drugs/tetrabik_july2012_e.pdf.
62. Vidor E., Plotokin A.A. Poliovirus vaccine-inactivated. Vaccines 2013, 573-597. Elsevier Saunders, Philadelphia, PA. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
63. National Institute of Infectious Diseases Fact sheet for poliovirus vaccine 2010, National Institute of Infectious Diseases, http://www.mhlw.go.jp/stf2/shingi2/2r9852000000bx23-att/2r9852000000bybl.pdf [in Japanese].
64. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008, 26:4978-4983.
65. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004, 292:1696-1701.
66. Sanofi Pasteur. [in Japanese] IMOVAX POLIO subcutaneous. http://www.info.pmda.go.jp/shinyaku/P201200053/650274000_22400AMX00684000_B100_2.pdf.
67. Ministry of Health Labour and welfare. A survey of vaccination coverage by routine OPV immunization in the spring of 2012 2012, Ministry of Health, 〈http://www.mhlw.go.jp/bunya/kenkou/polio/dl/121102-1.pdf〉 [in Japanese].
68. Nakatani H., Sano T., Iuchi T. Development of vaccination policy in Japan: current issues and policy directions. Jpn J Infect Dis 2002, 55:101-111.
69. Saitoh A., Okabe N. Current issues with the immunization program in Japan: can we fill the "vaccine gap"?. Vaccine 2012, 30:4752-4756.
70. Hosoda M., Inoue H., Miyazawa Y., Kusumi E., Shibuya K. Vaccine-associated paralytic poliomyelitis in Japan. Lancet 2012, 379:520.
71. Ministry of Health Labour and Welfare. On the immunization rates in JFY 2012 2014, Ministry of Health, 〈http://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000058662.pdf〉 [in Japanese].
72. Fujioka K., Iijima K. Imported inactibated polio vaccine use in Kobe city Nihon Shonika Gakkai Zasshi. J Jpn Pediatr Soc 2013, 117:766-772. [in Japanese].
73. Takayama N., Shimizu H., Umemoto T. A survey of the number of immunization with inctibvated poliovius vaccine, The survey results in 2011. J Jpn Med Assoc 2012, 141:1052-1058. [in Japanese].
74. Takayama N., Sakiyama H., Shimizu H., Umemoto T. Cummulative vaccination covrrage of oral poliovirus vaccine and inactivated poliovirus vaccine obtained by the nationwide survey in 2013. J Jpn Med Assoc 2014, 143:609-614. [in Japanese].
75. Ministry of Health Labour and welfare. Status of polio immunization and prevalence of antibodies against polioviruses-from a NESVPV survey in 2013 2014, 18. Ministry of Health, 〈http://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000045751.pdf〉 [in Japanese].
76. National Committee for the Certification of Poliomyelitis Eradication of Japan Country progress report on maintaining polio-free status for the 19th Regional Commission for the certification of poliomyelitis eradication in the Western Pacific 2013, 1-15. National Committee for the Certification of Poliomyelitis Eradication of Japan, Tokyo, Japan.
77. Pharmaceuticals and Medical Devices Agency Squarekids subcutaneous injection syringe 2014, Pharmaceuticals and Medical Devices Agency, 〈http://www.info.pmda.go.jp/go/pack/636140EG1026_1_01/〉 [in Japanese].
78. Takeda Pharmaceutical Company Limited Quadrivalent vaccine TAK-361S enters into phase II clinical trials in Japan 2011, Takeda Pharmaceutical Company Limited, 〈https://http://www.takeda.com/news/2011/20111116_3913.html〉 [in Japanese].
79. Ministry of Health Labour and Welfare. Immunogenicity and safety of OPV, IPV, and DPT-IPV in terms of interchangeably 2013, Ministry of Health, 〈http://www.mhlw.go.jp/stf/shingi/2r98520000036w4i-att/2rwc6_1_1.pdf〉 [in Japanese].
80. Murph J.R., Grose C., McAndrew P., Mickiewicz C., Mento S., Cano F., et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 1988, 7:760-765.
81. Verdijk P., Rots N.Y., van Oijen M.G., Weldon W.C., Oberste M.S., Okayasu H., et al. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 2014, 32:4938-4944.
82. Verdijk P., Rots N.Y., van Oijen M.G., Oberste M.S., Boog C.J., Okayasu H., et al. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine 2013, 31:5531-5536.
83. Liao G., Li R., Li C., Sun M., Li Y., Chu J., et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012, 205:237-243.
84. Yoshida H., Horie H., Matsuura K., Kitamura T., Hashizume S., Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 2002, 83:1107-1111.
85. Yoshida H., Horie H., Matsuura K., Miyamura T. Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan. Lancet 2000, 356:1461-1463.
86. Matsuura K., Ishikura M., Yoshida H., Nakayama T., Hasegawa S., Ando S., et al. Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture. Appl Environ Microbiol 2000, 66:5087-5091.
87. Tulchinsky T.H., Ramlawi A., Abdeen Z., Grotto I., Flahault A. Polio lessons 2013: Israel, the West Bank, and Gaza. Lancet 2013, 382:1611-1612.
88. Butler D. Polio risk looms over Europe. Nature 2013, 502:601-602.
89. Manor Y., Shulman L.M., Kaliner E., Hindiyeh M., Ram D., Sofer D., et al. Intensified environmental surveillance supporting the response to wild poliovirus type 1 silent circulation in Israel, 2013. Euro Surveill 2014, 19:20708.
90. Iwai-Itamochi M., Yoshida H., Obara-Nagoya M., Horimoto E., Kurata T., Takizawa T. Development of real-time PCR to detect oral vaccine-like poliovirus and its application to environmental surveillance. J Virol Methods 2014, 195:148-155.
91. Huang Q.S., Greening G., Baker M.G., Grimwood K., Hewitt J., Hulston D., et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet 2005, 366:394-396.
92. Jafari H., Deshpande J.M., Sutter R.W., Bahl S., Verma H., Ahmad M., et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014, 345:922-925.
93. Mangal T.D., Aylward R.B., Grassly N.C. The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting. Am J Epidemiol 2013, 178:1579-1587.
94. Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012, 8:e1002599.
95. Sun M., Ma Y., Xu Y., Yang H., Shi L., Che Y., et al. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine. Vaccine 2014, 32:1100-1106.
96. Resik S., Tejeda A., Fonseca M., Alemani N., Diaz M., Martinez Y., et al. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: A phase I Trial in healthy adults in Cuba. Vaccine 2014, 32:5399-5404.
97. Hamidi A., Bakker W.A. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Patent Analyst 2012, 1:589-599.
98. Verdijk P., Rots N.Y., Bakker W.A. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011, 10:635-644.
99. Bakker W.A., Thomassen Y.E., Van't Oever A.G., Westdijk J., van Oijen M.G., Sundermann L.C., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29:7188-7196.
100. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34:155-158.
101. World Health Organization WHO technical working group meeting on revision of the WHO recommen-dations for the production and control of inactivated poliomyelitis vaccines: TRS no. 910, Annex 1 2013, World Health Organization, 〈http://www.who.int/biologicals/areas/vaccines/IPV_Meeting_TRS_Revision_14-5_May_2013_Report_FINAL_22112013.pdf?ua=1〉.
102. Hagiwara A., Yoneyama T., Yoshii K., Yoshida H., Shimizu H., Wada J., et al. Genetic analysis of wild polioviruses towards the eradication of poliomyelitis from the Western Pacific Region. Jpn J Infect Dis 1999, 52:146-149.
103. Shimizu H., Nakashima K. Surveillance of hand, foot, and mouth disease for a vaccine. Lancet Infect Dis 2014, 14:262-263.
104. Pallansch M.A., Oberste M.S. Enterovirus 71 encephalitis: a new vaccine on the horizon?. Lancet 2013, 381:976-977.
105. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001, 20:63-75.
106. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014, 370:818-828.
107. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014, 370:829-837.
108. Zhu F.C., Liang Z.L., Li X.L., Ge H.M., Meng F.Y., Mao Q.Y., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013, 381:1037-1045.